ALORA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ALORA (ALORA).
Estradiol binds to estrogen receptors (ERα and ERβ), activating gene transcription and non-genomic signaling pathways, resulting in proliferation of endometrial tissue.
| Metabolism | Primarily hepatic via CYP3A4; undergoes enterohepatic recirculation; metabolites include estrone, estriol, and conjugates (glucuronides and sulfates). |
| Excretion | Alora (estradiol transdermal system) is eliminated primarily via hepatic metabolism, with approximately 60% of a dose excreted in urine as glucuronide and sulfate conjugates, and about 40% excreted in feces via biliary elimination. |
| Half-life | The terminal elimination half-life of estradiol is approximately 13-19 hours following transdermal administration, reflecting slow release from the skin depot and ongoing metabolism. This half-life allows for continuous hormone levels with once- or twice-weekly dosing. |
| Protein binding | Estradiol is approximately 97-99% bound to serum proteins, primarily sex hormone-binding globulin (SHBG) and albumin. The binding to SHBG is high affinity, while albumin binding is nonspecific and lower affinity. |
| Volume of Distribution | The apparent volume of distribution (Vd) of estradiol is approximately 5-10 L/kg, indicating extensive distribution into tissues including breast, adipose, and reproductive organs. This large Vd reflects sequestration in adipose tissue and other estrogen-sensitive tissues. |
| Bioavailability | The bioavailability of estradiol from the transdermal system is approximately 10% compared to oral administration, due to avoidance of first-pass hepatic metabolism. The absolute bioavailability relative to intravenous is near 100%, as transdermal delivery provides direct systemic absorption. |
| Onset of Action | Following transdermal application, estradiol is absorbed through the skin, with steady-state serum concentrations achieved within 12-24 hours. Clinical effects such as relief of vasomotor symptoms may be noticeable within 1-2 weeks of initiation. |
| Duration of Action | The duration of action for a single transdermal patch is 3-4 days, as serum estradiol levels remain within therapeutic range during the recommended application period. Patches are typically replaced twice weekly to maintain stable hormone concentrations. |
| Molecular Weight | 314.5 |
Estradiol (ALORA) transdermal patch: 0.025-0.1 mg/day applied twice weekly. Typical starting dose 0.05 mg/day.
| Dosage form | FILM, EXTENDED RELEASE |
| Renal impairment | No dose adjustment required for mild-moderate renal impairment (GFR >=30 mL/min). Not studied in severe impairment (GFR <30 mL/min); use with caution. |
| Liver impairment | Contraindicated in severe hepatic disease (Child-Pugh class C). For moderate impairment (Child-Pugh class B), use lowest effective dose and monitor. No adjustment for mild (Child-Pugh class A). |
| Pediatric use | Not approved for use in pediatric patients. Safety and efficacy not established. |
| Geriatric use | Use lowest effective dose and duration. Consider increased risk of cardiovascular events, thromboembolism, and malignancy. Starting dose 0.025 mg/day with gradual titration as needed. |
| 1st trimester | Progesterone use in first trimester is associated with hypospadias, but benefits may outweigh risks for luteal phase support. Avoid unless clearly indicated. |
| 2nd trimester | Generally considered safe when used for indicated conditions (e.g., preterm birth prevention). Monitor for adverse effects. |
| 3rd trimester | Use only for short-term, specific indications like prevention of preterm birth. Avoid prolonged use near term due to potential effects on placental function. |
Clinical note
Comprehensive clinical and safety monograph for ALORA (ALORA).
| Placental transfer | Progesterone crosses the placenta readily. Concentrations in fetal blood are approximately 5-10% of maternal levels. |
| Breastfeeding | Progesterone is excreted into breast milk in small amounts. No adverse effects reported in nursing infants. Use with caution, especially with high doses or prolonged therapy. |
■ FDA Black Box Warning
Estrogens increase the risk of endometrial cancer. Unopposed estrogen increases the risk of endometrial hyperplasia and carcinoma. Adequate diagnostic measures, including endometrial sampling if indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.
| Serious Effects |
Known hypersensitivity to progesterone or any excipientUndiagnosed vaginal bleedingSevere hepatic impairment or liver diseaseKnown or suspected pregnancy (except for luteal phase support indications)Active thromboembolic disorder or history of thrombophlebitis
| Precautions | Cardiovascular disorders (e.g., stroke, DVT, pulmonary embolism), probable dementia (increased risk in women ≥65 years), breast cancer, endometrial cancer, gallstones, hypertriglyceridemia, fluid retention, hypocalcemia, hereditary angioedema, and exacerbation of endometriosis. |
| Food/Dietary | No significant food interactions. Avoid grapefruit juice if on hormonal therapy as it may increase estrogen levels. |
Loading safety data…
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | ALORA (estradiol vaginal ring) is contraindicated in pregnancy. First trimester: estrogen exposure is associated with a risk of vaginal adenosis and clear cell adenocarcinoma in female offspring, as well as congenital anomalies including cardiac defects and limb reduction defects. Second and third trimesters: increased risk of fetal genital abnormalities and potential for long-term reproductive tract effects. Estrogens are not indicated for use during pregnancy. |
| Fetal Monitoring | Monitor for signs of thromboembolism (e.g., leg pain, chest pain, dyspnea), hypertension, and liver function abnormalities. In pregnancy, if accidental exposure occurs, perform ultrasound for fetal anatomy and growth. No routine fetal monitoring is indicated if ALORA is used appropriately (non-pregnant). |
| Fertility Effects | ALORA, as an estrogen, may inhibit ovulation and affect menstrual cycle regularity, potentially reducing fertility. Use for contraception is not sufficiently reliable. Fertility is expected to return upon discontinuation. |
| Clinical Pearls | ALORA 0.03% estradiol vaginal cream is indicated for atrophic vaginitis. Apply 1-2 g daily for 2 weeks, then taper. May cause endometrial hyperplasia if used without progestin in women with intact uterus. Avoid in breast cancer history. |
| Patient Advice | Use the measured applicator for correct dose. · Apply cream at bedtime for best absorption. · Wash applicator after each use with soap and water. · Report any abnormal vaginal bleeding immediately. · Do not use if allergic to estrogens. |